

The RACE-3 is on: Double-locking sinus rhythm by upstream and downstream therapy

Pavlovic, Davor; Kirchhof, Paulus; Fabritz, Larissa

DOI:

[10.1093/eurheartj/ehy018](https://doi.org/10.1093/eurheartj/ehy018)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Pavlovic, D, Kirchhof, P & Fabritz, L 2018, 'The RACE-3 is on: Double-locking sinus rhythm by upstream and downstream therapy', *European Heart Journal*, vol. 39, no. 32, pp. 2997–2999.
<https://doi.org/10.1093/eurheartj/ehy018>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy

Davor Pavlovic¹, Paulus Kirchhof^{1,2,3}, and Larissa Fabritz^{1,3*}

¹Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; ²Sandwell and West Birmingham NHS Trust, Birmingham, UK; and ³University Hospital Birmingham NHS Foundation Trust, Birmingham, UK

This editorial refers to ‘Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial’, by M. Rienstra et al. doi:10.1093/eurheartj/ehx739.

Recent advances in the field of anticoagulation have given us powerful tools to reduce stroke and its associated disease burden in patients with atrial fibrillation.^{1–4} More work needs to be done to offer adequate anticoagulation to all patients with atrial fibrillation at risk for stroke,^{5,6} and ongoing trials explore the limits of anticoagulation in patients with very low levels of atrial arrhythmias.^{7,8} However, even in adequately anticoagulated patients with atrial fibrillation, important unmet therapeutic needs remain, particularly around prevention of sudden death, heart failure, and unplanned cardiovascular hospitalizations.⁵

Many groups have speculated that ‘upstream therapy’ or ‘prevention of atrial remodelling’ can improve rhythm control therapy in patients with atrial fibrillation.^{9,10} Clinical trials conducted so far have not conclusively demonstrated effectiveness of either angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), or statins in reducing recurrent AF.^{11–13} In this issue of the journal, van Gelder and colleagues report the outcome of the RACE-3 study.¹⁴ RACE-3 tested whether the addition of a comprehensive ‘upstream therapy’ package, consisting of mineralocorticoid receptor antagonists (MRAs), statins, ACE-Is and/or ARBs, and cardiac rehabilitation including physical activity, dietary restrictions, and counselling, improves sinus rhythm maintenance in anticoagulated patients with persistent atrial fibrillation undergoing rhythm control therapy.⁹ This elegant design combines several important components of ‘upstream therapy’ into a single intervention, thus quantifying the positive effect of ‘upstream therapy’ in its totality for recurrent atrial fibrillation in 1 year.¹⁵

In RACE-3, patients randomized to the ‘upstream therapy’ intervention had lower blood lipid levels, lower levels of brain natriuretic peptide (BNP), and lower blood pressure than the control group at follow up, demonstrating that the intervention had the desired biological

effects. The feasibility of an intervention to reduce the cardiovascular risk profile in patients with atrial fibrillation is an important finding in itself and should empower primary and secondary prevention initiatives. The authors found a slightly higher number of patients in sinus rhythm after 1 year, with a nominally significant *P*-value (*P* = 0.04) in the primary outcome of the study, defined as sinus rhythm on at least 6 out of 7 days of a 7 day Holter ECG at 1 year follow-up. Other rhythm outcomes were not different between groups, e.g. the number of repeat cardioversions, the time to recurrent atrial fibrillation, or cardiovascular hospitalizations. This may be due to the weaker long-term and indirect effects of the intervention on atrial electrical function (*Take home figure*) which contrasts with the immediate direct effects of anti-arrhythmic drugs and ablation procedures. Of note, the use of ACE-Is/ARBs was high in both study groups, and catheter ablation was rarely used in the study population, with only seven ablations performed.

The results illustrate two main points: (i) a comprehensive ‘upstream therapy’ treatment package in patients with persistent atrial fibrillation and some degree of heart failure only slightly improves prevention of recurrent AF in the short term; and (ii) such treatment seems safe and leads to desirable reductions in lipid profiles, BNP, and blood pressure.

What does the study add?

Like every well-designed study, RACE-3 provides important answers and raises new questions. MRAs, statins, ACE-Is/ARBs, and cardiac rehabilitation improved important surrogates for cardiovascular outcomes without major safety concerns. As such, the study results demonstrate the feasibility of comprehensive cardiovascular risk reduction in patients with atrial fibrillation, supporting the concept of integrated care for these patients,^{15,6} as the authors discuss elegantly.¹⁴


RACE-3 also illustrates the limited short-term effectiveness of ‘upstream therapy’ for preventing recurrent atrial fibrillation after cardioversion: even a comprehensive package tackling underlying cardiovascular conditions by rehabilitation, statins, MRAs, and renin–

The opinions expressed in this article are not necessarily those of the Editors of the *European Heart Journal* or of the European Society of Cardiology.

* Corresponding author. Institute of Cardiovascular Sciences, University of Birmingham and UHB NHS Trust, IBR, Wolfson Drive, Birmingham B15 2TT, UK. Tel: +44 121 414 7042, Email: l.fabritz@bham.ac.uk

© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.



Take home figure Illustration of major upstream and downstream drivers of atrial fibrillation (AF) and direct and indirect links to cardiovascular outcomes. Upstream therapy targets major indirect drivers of AF, including high blood pressure, renin-angiotensin-aldosterone-system (RAAS) activation, reactive oxygen species (ROS), increased sodium load, dyslipoproteinemia and epicardial fat. Upstream therapy thus also reduces atrial load and strain, fibrosis and fat infiltration in the atria. Rhythm control therapy directly targets triggered activity, action potential duration (APD) shortening and slowed conduction across the atria. Inset; atrial electrical function can be altered by fatty deposition (shown in yellow) and interstitial fibrosis (shown in red). Dashed lines indicate less established links, solid lines established links to a delta of cardiovascular complications. ICV, inferior caval vein; LA, left atrium; LPV, left pulmonary vein; RA, right atrium; SAN, sinoatrial node.

angiotensin-aldosterone system (RAAS) inhibition did not affect the number of repeat cardioversions, time to recurrent atrial fibrillation, or cardiovascular hospitalizations. More efficient weight loss strategies could possibly also lead to better outcomes in the future, as there was only a slight decrease in body mass index in the intervention group in RACE-3. Longer term assessment of the intervention tested in RACE-3 may provide further benefits to the patients as the 'upstream therapy' package may have more pronounced effects on atrial fibrillation after several years of treatment. We look ahead for the long-term follow-up of this patient cohort for answers to these questions.

What does that mean for clinical practice?

MRA inhibition, RAAS inhibition, and statins should be considered in patients with persistent atrial fibrillation as part of an integrated approach to the care of patients with atrial fibrillation.^{5,6} The results also illustrate that the effect of 'upstream therapy' on recurrent atrial fibrillation in patients with persistent atrial fibrillation is modest at best, and clearly weaker than the short-term effect of antiarrhythmic drug therapy or catheter ablation.^{21,22} Testing the effectiveness of 'upstream therapy' over a longer time frame may still demonstrate that such treatments lead to better outcomes. Nevertheless, targeted and direct treatment of electrical drivers of AF is needed to improve rhythm control therapy, e.g. early rhythm control interventions,^{18,23} hybrid therapy incorporating catheter ablation and

antiarrhythmic drugs,^{1,16,17} and treatment approaches based on the major drivers of atrial fibrillation (*Take home figure*).¹⁵

More upstream and downstream work is needed

The results of RACE-3 illustrate that risk factor management cannot replace direct treatment of the electrical drivers of atrial fibrillation by antiarrhythmic drugs and catheter ablation (*Take home figure*). While we await the full publication of the CASTLE-AF trial outcome, the next few years should provide new information on the role of modern and comprehensive rhythm control therapy for cardiovascular outcomes in patients with atrial fibrillation.^{16–18} In addition, there is a clear need to improve rate control therapy to avoid worsening of heart failure in patients with atrial fibrillation, including mechanistic work to identify patients who benefit from specific treatments.^{19,20}

Clearly, the road to successful maintenance of sinus rhythm requires careful consideration of the major health modifiers causing atrial fibrillation. A substantial body of evidence demonstrates that atrial fibrillation and other underlying cardiovascular conditions alter structural and electrical properties of the atria,^{10,15} including interstitial fibrosis, increased formation of extracellular matrix, alterations in cell-cell contact proteins, adipose tissue activation and infiltration, changes in gene expression pattern, oxidative stress, calcium abnormalities, and others. Dysregulation of the RAAS and autonomic dysfunction are found in atrial fibrillation, hypertension, heart failure,

kidney dysfunction, or obesity, and further promote atrial remodeling. Early-onset atrial fibrillation in particular can be driven by a genetic or genomic component that must also be taken into consideration during treatment. Attenuation of such complex pathophysiological stimuli requires a collaborative effort of basic and clinical arms of our research, if we are to tackle the ever-increasing incidence and prevalence of atrial fibrillation.

The double lock

Joint upstream and downstream therapy can provide a double lock to slow progression of the atrial fibrillation, but more work needs to be done. The results of RACE-3 thus call for a full-scale effort to tighten rhythm control therapy upstream and downstream, considering the major drivers of recurrent atrial fibrillation in patients by stratified therapy.

Funding

This work was partially supported by the European Union [grant agreement no. 633196 (CATCH ME) to P.K. and L.F.], the British Heart Foundation (FS/13/43/30324 to P.K. and L.F., PG/17/55/33087 to D.P.), and the Leducq Foundation to P.K.

Conflict of interest: P.K. receives additional research support from the Medical Research Council (UK), the German Centre for Cardiovascular Research, and from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies. P.K. and L.F. are listed as inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783).

References

- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias A, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016;**37**:2893–2962.
- Camm AJ, Amarencu P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J* 2016;**37**:1145–1153.
- Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events–European Registry in Atrial Fibrillation (PREFER in AF). *Europace* 2014;**16**:6–14.
- Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). *Eur Heart J* 2014;**35**:3365–3376.
- Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. *Lancet* 2017;**390**:1873–1887.
- Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P. European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their healthcare providers. *Europace* 2017; doi:10.1093/eurpace/eux299.
- Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. *Am Heart J* 2017;**190**:12–18.
- Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESIA) trial. *Am Heart J* 2017;**189**:137–145.
- Alings M, Smit MD, Moes ML, Crijns HJ, Tijssen JG, Bruggemann J, Hillege HL, Lane DA, Lip GY, Smeets JR, Tieleman RG, Tukkier R, Willems FF, Vermond RA, Van Veldhuisen DJ, Van Gelder IC. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. *Neth Heart J* 2013;**21**:354–363.
- Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. *J Am Coll Cardiol* 2014;**63**:2335–2345.
- Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial fibrillation. *N Engl J Med* 2009;**360**:1606–1617.
- Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T. Angiotensin II-antagonism in paroxysmal atrial fibrillation (ANTIPAF) trial. *Circ Arrhythm Electrophysiol* 2012;**5**:43–51.
- Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Perioperative rosuvastatin in cardiac surgery. *N Engl J Med* 2016;**374**:1744–1753.
- Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Bruggemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkier R, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; for the RACE 3 Investigators. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. *Eur Heart J* 2017; doi:10.1093/eurheartj/ehx739.
- Fabritz L, Guasch E, Antoniadou C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Carlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kaab S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. *Nat Rev Cardiol* 2016;**13**: 230–237.
- Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options—a report from the 3rd Atrial Fibrillation Competence NETWORK/European Heart Rhythm Association consensus conference. *Europace* 2012;**14**:8–27.
- Duytschaever M, Demolder A, Philips T, Sarkozy A, El Haddad M, Taghji P, Knecht S, Tavernier R, Vandekerckhove Y, De Potter T. Pulmonary vein isolation With vs. without continued antiarrhythmic Drug treatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. *Eur Heart J* 2017; doi: 10.1093/eurheartj/ehx666.
- Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. *Am Heart J* 2013;**166**:442–448.
- Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GY, Mehta S, Slinn G, Stanbury M, Steeds RP, Townend JN. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. *BMJ Open* 2017;**7**: e015099.
- Shantsila E, Haynes R, Calvert M, Fisher J, Kirchhof P, Gill PS, Lip GY. Improved exercise tolerance in patients with Preserved Ejection fraction by Spironolactone on myocardial fibrosis in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. *BMJ Open* 2016;**6**:e012241.
- Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P. Approaches to catheter ablation for persistent atrial fibrillation. *N Engl J Med* 2015;**372**:1812–1822.
- Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. *N Engl J Med* 2012;**367**:1587–1595.
- Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, Conroy JM, Al-Khatib SM, Hess PL, Kirchhof P, De Bono J, Lip GY, Banerjee A, Ruskin J, Blendea D, Camm AJ. Early management of atrial fibrillation to prevent cardiovascular complications. *Eur Heart J* 2014;**35**:1448–1456.